WAVE LIFE SCIENCES LTD. (WVE) Spending and interest coverage
- R&D / revenue · 12 months: Value 302.00%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 302.00% | Research and development expense / revenue. Period ending 2026-06-30. $197.42M ÷ $65.37M × 100 ≈ 302.00% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 197.42M USD | Research and Development Expense |
| Revenue | 65.37M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -217.92M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $197.42M | $65.37M | (m) | $-217.92M | (m) | 302.00% | (m) | (m) | (m) |
| 2026-03-31 | $189.60M | $71.80M | (m) | $-196.88M | (m) | 264.07% | (m) | (m) | (m) |
| 2025-12-31 | $182.78M | $42.73M | (m) | $-215.38M | (m) | 427.78% | (m) | (m) | (m) |
| 2025-09-30 | $174.61M | (m) | (m) | $-135.95M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $169.93M | $93.95M | (m) | $-143.51M | (m) | 180.88% | (m) | (m) | (m) |
| 2025-03-31 | $166.86M | $104.94M | (m) | $-125.75M | (m) | 159.00% | (m) | (m) | (m) |
| 2024-12-31 | $159.68M | $108.30M | (m) | $-110.40M | (m) | 147.44% | (m) | (m) | (m) |
| 2024-09-30 | $149.11M | (m) | (m) | $-152.05M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $139.56M | $110.50M | (m) | $-83.69M | (m) | 126.30% | (m) | (m) | (m) |
| 2024-03-31 | $132.48M | $112.91M | (m) | $-72.17M | (m) | 117.33% | (m) | (m) | (m) |
| 2023-12-31 | $130.01M | $113.31M | (m) | $-68.00M | (m) | 114.74% | (m) | (m) | (m) |
| 2023-09-30 | $127.01M | $85.49M | (m) | $-92.88M | (m) | 148.57% | (m) | (m) | (m) |
| 2023-06-30 | $122.95M | $36.56M | (m) | $-136.22M | (m) | 336.29% | (m) | (m) | (m) |
| 2023-03-31 | $119.36M | $14.83M | (m) | $-154.91M | (m) | 805.00% | (m) | (m) | (m) |
| 2022-12-31 | $115.86M | $3.65M | (m) | $-162.72M | (m) | 3175.01% | (m) | (m) | (m) |
| 2022-09-30 | $110.54M | $4.17M | (m) | $-155.27M | (m) | 2647.64% | (m) | (m) | (m) |
| 2022-06-30 | $114.05M | $40.31M | (m) | $-123.97M | (m) | 282.91% | (m) | (m) | (m) |
| 2022-03-31 | $115.95M | $42.71M | (m) | $-121.64M | (m) | 271.46% | (m) | (m) | (m) |
| 2021-12-31 | $121.88M | $40.96M | (m) | $-127.02M | (m) | 297.52% | (m) | (m) | (m) |
| 2021-09-30 | $126.15M | $48.64M | (m) | $-121.22M | (m) | 259.36% | (m) | (m) | (m) |
| 2021-06-30 | $123.34M | $15.66M | (m) | $-148.03M | (m) | 787.33% | (m) | (m) | (m) |
| 2021-03-31 | $123.18M | (m) | (m) | $-146.85M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $130.94M | $20.08M | (m) | $-153.38M | (m) | 652.21% | (m) | (m) | (m) |
| 2020-09-30 | $150.04M | $13.04M | (m) | $-183.60M | (m) | 1150.78% | (m) | (m) | (m) |
| 2020-06-30 | $166.35M | $12.52M | (m) | $-203.36M | (m) | 1328.98% | (m) | (m) | (m) |
| 2020-03-31 | $176.48M | $17.12M | (m) | $-210.32M | (m) | 1030.94% | (m) | (m) | (m) |
| 2019-12-31 | $175.43M | $15.98M | (m) | $-208.32M | (m) | 1097.61% | (m) | (m) | (m) |
| 2019-09-30 | $166.11M | $17.20M | (m) | $-196.73M | (m) | 965.60% | (m) | (m) | (m) |
| 2019-06-30 | $154.40M | $18.77M | (m) | $-180.78M | (m) | 822.74% | (m) | (m) | (m) |
| 2019-03-31 | $145.34M | $16.02M | (m) | $-171.74M | (m) | 907.39% | (m) | (m) | (m) |
| 2018-12-31 | $134.43M | $14.41M | (m) | $-159.52M | (m) | 932.62% | (m) | (m) | (m) |
| 2018-09-30 | $119.99M | $11.70M | (m) | $-141.93M | (m) | 1025.28% | (m) | (m) | (m) |
| 2018-06-30 | $107.21M | $8.53M | (m) | $-130.05M | (m) | 1257.58% | (m) | (m) | (m) |
| 2018-03-31 | $93.77M | $4.74M | (m) | $-118.15M | (m) | 1976.91% | (m) | (m) | (m) |
| 2017-12-31 | $79.31M | $3.70M | (m) | $-102.58M | (m) | 2141.17% | (m) | (m) | (m) |
| 2017-09-30 | $67.94M | $2.70M | (m) | $-90.50M | (m) | 2512.39% | (m) | (m) | (m) |
| 2017-06-30 | $61.52M | $2.42M | (m) | $-80.75M | (m) | 2542.31% | (m) | (m) | (m) |
| 2017-03-31 | $50.82M | $2.16M | (m) | $-67.29M | (m) | 2351.78% | (m) | (m) | (m) |
| 2016-12-31 | $40.82M | $1.49M | (m) | $-55.33M | (m) | 2748.69% | (m) | (m) | (m) |
| 2016-09-30 | $30.29M | $809.00K | (m) | $-44.04M | (m) | 3744.25% | (m) | (m) | (m) |
| 2016-06-30 | $18.74M | $417.00K | $3.67M | $-31.79M | (m) | 4493.29% | 879.62% | (m) | (m) |
| 2016-03-31 | $12.19M | (m) | $3.04M | $-23.79M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $9.06M | $152.00K | $4.02M | $-19.30M | (m) | 5958.55% | 2647.37% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $2.40M | (m) | (m) | $-5.39M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $1.92M | (m) | (m) | $-3.57M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |